$DOCS

Sitaram Siddharth sold $50K of DOCS

Sitaram Siddharth (Interim PAO) sold 2,444 shares of Doximity, Inc. (DOCS) at $20.41 on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sitaram Siddharth
Published Jun 10, 2026, 8:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DOCS
Neutral
high confidence
Mentioned
$DOCS
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DOCSNeutralLow
01

Why it matters

The disclosure confirms an officer’s scheduled open-market sale of DOCS shares; absent additional context, it is usually not a fundamental catalyst.

02

Market read

Confirms modest insider selling in DOCS under a 10b5-1 plan; likely limited trading impact.

03

What to watch

Traders may ignore that the sale date (2026-06-08) precedes the filing; any price reaction would be more likely tied to other contemporaneous news than this Form 4.

Relevance 2/10Novelty 8/10Timing: filed 2026-06-10 (sale dated 2026-06-08)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Doximity, Inc.

Company-level read

Ticker impact

$DOCSNeutralHigh confidence
Context

Insider Form 4 shows Doximity officer Sitaram Siddharth sold 2,444 shares in an open-market transaction on 2026-06-08 under a 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely sentiment-only and quickly absorbed.

Evidence & confidence

The filing is a disclosed insider sale (not a buy), but it is explicitly under a pre-arranged 10b5-1 plan and the disclosed size is modest versus typical liquidity.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is on a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Doximity, Inc.

    DOCS, the company whose insider transaction is disclosed.

  • Sitaram Siddharth

    Interim PAO who sold 2,444 shares under a 10b5-1 plan.

  • 10b5-1 plan

    Pre-arranged plan that reduces interpretability of insider intent.

Related articles

$DOCSMed

Why Doximity Stock Skyrocketed on Friday

Doximity (NYSE: DOCS) shares rose after CEO Jeff Tangney said early returns from the company’s AI investments are improving profitability. In fiscal 2027 Q1 ended June 30, revenue increased 7% to $156.6M, while adjusted EBITDA fell 6% to $74.8M. Tangney cited >25% QoQ AI prompt volume growth and 10x AI Scribe users, plus revenue exceeding 10x search costs.

$DOCSMedAI 8/10

Doximity Q1 Earnings Call Highlights

Doximity (NYSE:DOCS) reported Q1 results, citing its expert-verified drug reference and physician-reviewed AI tools. It said it has 165 live health-system AI clients, including Northwestern, Penn Medicine and Michigan. AI Search launched in late April; no Q1 revenue recognized, with most expected in fiscal Q3. Q1 revenue retention: 112% top 20, 107% overall. Q2 revenue forecast $170M-$171M; FY2027 outlook raised to $671M-$681M.

$DOCSHighAI 9/10

A Lesser-Known Stock Climbed More Than 100% In a Day After AI Surprise. Here’s Why.

Doximity (DXRX) shares jumped after the company reported fiscal Q1 2027 results and said its new AI search product is generating strong unit economics. CEO Jeffrey Tangney said revenue is over 10 times per search versus cost. Q1 revenue was $156.6M and adjusted EBITDA $74.8M. Full-year revenue guidance raised to $671M-$681M; short interest was about 17%, contributing to a short squeeze.

$DOCSMedAI 8/10

Why Doximity Stock Is Up 80%

Doximity (NYSE:DOCS) shares jumped about 80% after CEO Jeffrey Tangney said its new AI search tool generates over 10 times more revenue per search than it costs. The company reported Q revenue up 7% to $156.6M and adjusted EBITDA of $74.8M, and raised full-year revenue guidance to $671M-$681M. FactSet said 17% of tradable shares were short before the report.